Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Hundreds of Fosamax lawsuits versus Merck ordered readied for trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/30/2013 | 10:53pm CET

A federal judge overseeing consolidated litigation against Merck & Co over jaw injuries allegedly caused by the osteoporosis drug Fosamax has ordered hundreds of cases be dispersed to courts across the country for trial.

The decision by U.S. District Judge John Keenan in Manhattan marks an unusual and potentially costly development for Merck.

Companies often find it easier to reach settlements in mass tort cases that are consolidated before one judge.

"It's a big deal as it changes the cost paradigm for Merck exponentially," said Timothy O'Brien, a partner at Levin, Papantonio, Thomas, Mitchell, Rafferty & Proctor and lawyer representing Fosamax plaintiffs.

The judge's order Thursday requires that 200 cases per month be sent to back to courts where they were initially filed, beginning with the oldest ones.

Lainie Keller, a spokeswoman for Merck, said the company "is committed to defending its conduct in regard to Fosamax and has confidence in its defense strategy that has had so much success in the courts."

The cases before Keenan comprised roughly one-fifth of the 5,075 lawsuits pending nationally in federal and state courts related to Fosamax, a one-time blockbuster medication.

Lawsuits alleging that plaintiffs developed osteonecrosis of the jaw from Fosamax were consolidated before Keenan in 2006.

The judge conducted a series of "bellwether" trials, allowing the parties to assess trends and outcomes in similar cases. A series of wins for plaintiffs, for example, can put them in a better position for settlement talks.

The final Fosamax bellwether trial before Keenan ended in February with a $285,000 verdict for plaintiff Rhoda Scheinberg.

Merck lost just one other of the five bellwether trials before Keenan, when a jury in 2010 awarded Florida resident Shirley Boles $8 million, a sum the judge reduced to $1.5 million.

Keenan's order on Friday came after mediation to resolve 370 cases broke down two weeks ago. O'Brien's law firm and another firm represented plaintiffs in those cases.

Another 104 lawsuits brought by another firm could have been added to the talks if a deal on value was reached, O'Brien said.

Lawyers for the plaintiffs had sought to have 300 cases transferred every four months, while Merck sought to have just 100 cases scheduled for discovery over a six-month period.

Merck has benefited from having the litigation consolidated.

Keenan had thrown out 430 cases after he issued an order last November, which Merck had sought, requiring them to put forth expert reports showing scientific proof of their claims.

But in his order Friday, Keenan said Merck's latest proposal would "unnecessarily prolong" the proceedings before him.

Keenan ordered plaintiffs to recommend by October 11 where to sent the first batch of cases.

An order moving so many personal injury cases home at once is rare, O'Brien said. He noted that Merck reached a $4.85 billion settlement with over the painkiller Vioxx in 2007 only after a federal judge threatened a similar order.

"I anticipate Merck will continue talking and seek to resolve the cases," O'Brien said. "The opportunity is there."

The case is In Re Fosamax Products Liability Litigation, U.S. District Court, Southern District of New York, No. 06-md-01789.

(Reporting by Nate Raymond in New York; Editing by Bernard Orr)

By Nate Raymond

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
12/02 MERCK & CO., INC (NYSE : MRK) Gets Coveted Approval For Keytruda
12/02 Pharma execs weigh in on possible changes under Trump
12/01 MERCK : Global Protein Labeling Market is expected to grow at a CAGR of 12.2 % d..
12/01 MERCK : FDA Grants Priority Review to Supplemental Biologics License Application..
11/30 MERCK : New KEYTRUDA® (pembrolizumab) Data to be Presented at 17th World Confere..
11/29 MERCK : Declares Dividend of $0.4700.
11/29 MERCK : Actress Bellamy Young, Merck, and Leading Lung Cancer Advocates Urge Tho..
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
11/28 MERCK : FDA Grants Priority Review to Merck’s Supplemental Biologics Licen..
11/28DJAmazon Broadens Cloud Services as Big Companies Sign On
More news
Sector news : Pharmaceuticals - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:03a Barron's searches for value in its top stock picks for 2017
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/01 The Big Gamble
12/01 WisdomTree Equity Income ETF (DHS) November Summary
12/01 Invesco Equity and Income Fund A (ACEIX) November Summary
Advertisement
Financials ($)
Sales 2016 39 888 M
EBIT 2016 13 690 M
Net income 2016 5 904 M
Debt 2016 4 610 M
Yield 2016 3,03%
P/E ratio 2016 29,45
P/E ratio 2017 18,46
EV / Sales 2016 4,34x
EV / Sales 2017 4,32x
Capitalization 168 544 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 68,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.15.85%168 544
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
SANOFI-4.20%103 510
More Results